Ciprofloxacin Articles
FDA seeks to reassure US antibiotics makers
12 November 2001
US bill to ease urgent generic Rx production
12 November 2001
IVAX to make doxycycline as anthrax treatment in USA
6 November 2001
S Africa urges WTO pro-health TRIPs move
31 October 2001
Bayer paid $200M to keep generic Cipro off market, says lawsuit
31 October 2001
IVAX profits leap, but Onxol disappoints
29 October 2001
Indian firms prepare to make anti-anthrax drugs
24 October 2001
Canada Health backs down on buying Cipro from generics firms
24 October 2001
Now US Senate passes pediatric test bill
23 October 2001
Bayer commits to supply 200 million Cipro tabs over 3 mths
17 October 2001
Bayer's Cipro sales rise on anthrax fears
10 October 2001
Cipla signs deal with IVAX affiliate
5 September 2001
Court frees 7 drugs from India's DPCO
3 September 2001
Ranbaxy's Cifran approved in India
22 August 2001
Salix' rifaximin for infectious diarrhea
31 May 2001
Indian essential drugs' price curbs "must stay"
21 May 2001
Ranbaxy to buy stake in German Remedies?
13 March 2001
Barr Labs sees last qtr 2000 earnings up 33%
16 February 2001
W-A's Premarin is top US formulary drug
29 November 2000
Indian bulk drug firms warned on overpricing
18 September 2000
Bayer gets FDA OK for Cipro anthrax use
4 September 2000
Operating income up 31% at Bayer
10 August 2000
Bayer's Cipro backed for anthrax exposure
2 August 2000
"Greed vs need" in US brand/generic deals
26 July 2000
Ranbaxy in talks for two compounds
7 July 2000
Ranbaxy set to get $15 million from Bayer
19 June 2000
Stock Commentary Tokyo
15 June 2000
Ranbaxy forecasting strong growth in 2000
22 May 2000
Bayer's US health care sales jump 21% in 1999
31 March 2000
Bayer structure to remain intact UPDATE
20 March 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
Bayer's quinolone moxifloxacin approved in USA
16 December 1999
Bayer looking to Japan or the USA for a partner instead of Europe
17 November 1999
Daiichi Pharma sales growth slower; Harmokisan approval delayed
15 November 1999
Johnson & Johnson wins FDA panel backing for Levaquin in CAP
21 October 1999
Ranbaxy to take majority stake in Vorin
11 October 1999
Ranbaxy to get $60m from Bayer
16 September 1999
Ranbaxy to receive $65 million from Bayer?
2 September 1999
Ranbaxy to receive $65 million from Bayer?
26 August 1999
Bayer chief executive satisfied with first-half 1999 results
12 August 1999
Ranbaxy lining up new drug delivery system
9 July 1999
CPMP votes for year suspension of Trovan
17 June 1999
India raises prices of three bulk drugs
26 February 1999
India's Dr Reddy's To Float JV In Brazil
9 October 1998
Alcon Licenses Bayer Ear Infection Line
8 October 1998
Bayer AG Setting Up Indian Joint Venture
3 July 1998
Bayer Looking At Strong Growth, New Products
18 June 1998
US Generics Sector "Lacks Political Clout"
16 June 1998
Positive Presentations At Goldman Sachs Conf
15 June 1998
US Generics Sector "Lacks Political Clout"
12 June 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
Dr Reddy's 1997-98 Profits Climb 45%
5 May 1998
Bayer "Unperturbed" By Wave Of Mergers
18 March 1998
Bayer On Track For Record Growth In 1997
13 November 1997
Will New Wave Of Antibiotics Fight Resistance?
23 October 1997
India: "Price Control On 75 More Drugs"
7 October 1997
Laboratorios SALVAT R&D Policy Bears Fruit
21 August 1997
Ranitidine Bulk Prices Cut 30% By Indian Govt
13 August 1997
Indian Price-Fixing Case In High Court
29 July 1997
Bayer Opens Pharma Plant In Pakistan
11 July 1997
Glaxo Wellcome's Promising New Antibiotic
10 July 1997
Glaxo Wellcome's Promising New Antibiotic
8 July 1997
UK Industry Code Of Practice Review
2 July 1997
New Data With Glaxo Wellcome's Raxar
9 June 1997
Rhone-Poulenc Reorganizes In India
7 April 1997
Bayer Health Care Sales Fueled By Older Products
25 March 1997
Bayer Pharma Starts New Product Cycle
20 March 1997
Bayer Settles Barr-Rugby Generics Dispute
3 February 1997
Bayer/Barr Settlement
27 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Lack Of New Drugs To Fight Resistant Infections
9 September 1996
Bayer Completes $9.5M Venezuela Investment
12 August 1996
UK Industry Code of Practice Review
8 July 1996
Ophthalmic Ciprofloxacin
29 April 1996
Barr Mounts Challenge To US Patents For Prozac
22 April 1996
Bayer Details Near-Term Product Expectations
1 April 1996
NAFTA "Investor-State" Suit Against Canada
1 April 1996
More Restructuring At Bayer Despite Strong 1995
25 March 1996
Cipro For Cystic Fibrosis
18 March 1996
European Hospital Use Of Antibiotics In 1995
18 March 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
Bayer Develops Business Abroad
9 October 1995
FDA Panel Turns Down Monurol NDA
31 July 1995
Bayer Broadens Research Efforts: Part Two
26 June 1995
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
